APG Asset Management N.V. Sells 3,288 Shares of Illumina, Inc. $ILMN

APG Asset Management N.V. cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 33.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,467 shares of the life sciences company’s stock after selling 3,288 shares during the quarter. APG Asset Management N.V.’s holdings in Illumina were worth $475,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Moors & Cabot Inc. increased its stake in shares of Illumina by 2.5% in the 1st quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock worth $465,000 after acquiring an additional 145 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Illumina by 3.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after acquiring an additional 164 shares in the last quarter. Probity Advisors Inc. increased its stake in shares of Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company’s stock worth $274,000 after acquiring an additional 224 shares in the last quarter. Xponance Inc. increased its stake in shares of Illumina by 1.0% in the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company’s stock worth $2,123,000 after acquiring an additional 264 shares in the last quarter. Finally, Rakuten Securities Inc. increased its stake in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 270 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $99.54 on Thursday. The firm’s 50-day moving average price is $98.74 and its 200-day moving average price is $88.71. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The company has a market cap of $15.30 billion, a PE ratio of 12.60, a PEG ratio of 2.22 and a beta of 1.37. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research reports. Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and decreased their price target for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective for the company. in a research note on Friday, July 11th. Finally, Robert W. Baird raised their price objective on shares of Illumina from $84.00 to $105.00 and gave the company a “neutral” rating in a research note on Monday, July 28th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $123.17.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.